Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
January 2016
in “
Frontiers in immunology
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the potential of low-dose interleukin-2 (IL-2) therapy to treat Type 1 Diabetes (T1D) by expanding regulatory T cells (Tregs) to restore immune tolerance and prevent autoimmune destruction of pancreatic beta cells. Studies, including a phase 1/2 trial with 24 patients, showed that low-dose IL-2 was well-tolerated and increased Tregs without significantly affecting other immune cells. The therapy also showed promise in treating other autoimmune diseases like alopecia areata and graft-versus-host disease (GVHD). However, further research with larger sample sizes and reliable biomarkers is needed to confirm long-term efficacy and optimize dosing strategies.
